First Concussion Blood Test Leverages De Novo, Breakthrough Pathways
Executive Summary
The Banyan Brain Trauma Indicator is the first blood test for detecting concussions in adults to reach the US market and the second device to emerge from US FDA's Breakthrough Devices Program. While test-maker Banyan Biomarkers originally flirted with the PMA pathway, FDA swayed it to the de novo process, which the firm ultimately leveraged to gain the market go-ahead.
You may also be interested in...
Abbott’s Blood Test For Traumatic Brain Injury Succeeds In Landmark Trial
A landmark trial of Abbott Laboratories' point-of-care blood test for traumatic brain injuries shows the test could identify patients who should undergo magnetic resonance imaging (MRI), even after a computed tomography (CT) scan did not show a brain injury.
Into 2019: Stakeholders Are Bidding To Re-Engage Medtech's Innovative Engine
"All-hands-on-deck" has been the policy pursued by the US industry association AdvaMed in recent times, as it has sought to play its part in promoting user-friendly, responsive and transparent regulation and market access for medical and digital health care technology. AdvaMed chair Nadim Yared believes that, with one or two noteworthy exceptions, there is more to come in 2019 from a largely improving medtech ecosystem globally.
Military Products Will Get US FDA Fast-Track Review
FDA and the US Department of Defense launched a program to prioritize development of medical products for use in the battlefield. The program implements recently enacted compromise legislation that resolved a turf battle between the two agencies.